Farther Finance Advisors’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$87.7K Buy
1,007
+648
+181% +$39.1K ﹤0.01% 2808
2026
Q1
$15.1K Sell
359
-446
-55% -$16.7K ﹤0.01% 3841
2025
Q4
$28K Sell
805
-164
-17% -$12.9K ﹤0.01% 3206
2025
Q3
$80.5K Buy
969
+59
+6% +$4.27K ﹤0.01% 2165
2025
Q2
$66.8K Buy
910
+669
+278% +$48.5K ﹤0.01% 1986
2025
Q1
$22.1K Buy
241
+72
+43% +$4.38K ﹤0.01% 2341
2024
Q4
$8.52K Sell
169
-89
-34% -$4.66K ﹤0.01% 2446
2024
Q3
$11.9K Sell
258
-2,479
-91% -$88.1K ﹤0.01% 2301
2024
Q2
$89.4K Buy
2,737
+2,632
+2,507% +$72.1K ﹤0.01% 1177
2024
Q1
$2.7K Sell
105
-28
-21% -$662 ﹤0.01% 2364
2023
Q4
$4.32K Buy
133
+27
+25% +$741 ﹤0.01% 2045
2023
Q3
$2.89K Buy
106
+5
+5% +$145 ﹤0.01% 1717
2023
Q2
$2.25K Hold
101
﹤0.01% 1716
2023
Q1
$2.19K Hold
101
﹤0.01% 1614
2022
Q4
$2.05K Buy
+101
New +$2.53K ﹤0.01% 1439

Other funds holding CORT

Farther Finance Advisors's CORT Position: Q2 2026 in Review

Farther Finance Advisors increased its Corcept Therapeutics (CORT) stake by 181% in Q2 2026, buying an estimated $39.1K and bringing the position to 1,007 shares worth $87.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

Farther Finance Advisors first reported a position in CORT in Q4 2022 and has held it in 15 quarters since. The position peaked at $89.4K in Q2 2024. 61 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Farther Finance Advisors held 1,007 shares of Corcept Therapeutics worth $87.7K as of Q2 2026.
  • Farther Finance Advisors bought 648 Corcept Therapeutics shares in Q2 2026, an estimated $39.1K.
  • Corcept Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #2808 holding.
  • Farther Finance Advisors first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Corcept Therapeutics position peaked at $89.4K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.